Reply
Jean‐Charles Nault, Julien Calderaro, Jessica Zucman‐Rossi – 4 April 2015
Hepatorenal syndrome: The last pieces of the puzzle or not yet?
Isabel Graupera, Pere Ginès – 4 April 2015
Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis
Elliot B. Tapper, Daniel Finkelstein, Murray A. Mittleman, Gail Piatkowski, Michelle Lai – 4 April 2015 – The risk of morbidity and mortality for hospitalized patients with cirrhosis is high and incompletely captured by conventional indices. We sought to evaluate the predictive role of frailty in an observational cohort study of inpatients with decompensated cirrhosis between 2010 and 2013. The primary outcome was 90‐day mortality. Secondary outcomes included discharge to a rehabilitation hospital, 30‐day readmission, and length of stay.
Projections in donor organs available for liver transplantation in the United States: 2014‐2025
Neehar D. Parikh, David Hutton, Wesley Marrero, Kunal Sanghani, Yongcai Xu, Mariel Lavieri – 3 April 2015 – With the aging US population, demographic shifts, and obesity epidemic, there is potential for further exacerbation of the current liver donor shortage. We aimed to project the availability of liver grafts in the United States.
Correction
3 April 2015
Correction
3 April 2015
Right lobe split liver transplantation versus whole liver transplantation in adult recipients: A systematic review and meta‐analysis
Ping Wan, Qigen Li, Jianjun Zhang, Qiang Xia – 2 April 2015 – Split liver transplantation (SLT) has proven to be an effective technique to reduce the mortality of children on the waiting list, but whether creating 2 split grafts from 1 standard‐criteria whole liver would compromise outcomes of adult recipients remains uncertain. We conducted this meta‐analysis to compare outcomes of right lobe SLT and whole liver transplantation (WLT) in adult patients. PubMed, Embase, and the Cochrane Library were searched for relevant articles published before December 2014.
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy
Ilker Turan, Suna Yapali, Fikret Bademkiran, Timur Kose, Soner Duman, Murat Sozbilen, Fulya Gunsar, Galip Ersoz, Ulus Salih Akarca, Omer Ozutemiz, Zeki Karasu – 2 April 2015 – The recently reported benefit of telbivudine for renal function has not been systematically studied in long‐term liver transplantation (LT) recipients who are at high risk for renal impairment. We aimed to examine whether switching lamivudine therapy to telbivudine could improve renal function in LT recipients who have impaired renal function.
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David Wyles, Paul Pockros, Giuseppe Morelli, Ziad Younes, Evguenia Svarovskaia, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, John G. McHutchison, Steven Flamm, Eric Lawitz – 2 April 2015 – Patients who fail to achieve sustained virological response (SVR) after treatment with sofosbuvir (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg‐IFN) do not have established retreatment options.
Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis
Jonathan G. Stine, Neeral L. Shah, Curtis K. Argo, Shawn J. Pelletier, Stephen H. Caldwell, Patrick G. Northup – 2 April 2015 – Portal vein thrombosis (PVT) is a common complication of cirrhosis sometimes implicated in hepatic decompensation. There are no consistent epidemiologic data to suggest an increased risk of thrombotic complications in nonalcoholic steatohepatitis (NASH); however, research suggests an increased risk of thrombosis.